Business context and reporting period
Haemonetics Corporation is a global medical-products and solutions company serving plasma collection, blood centers and hospitals. This Form 10-Q covers the quarter ended September 30, 2023 (fiscal Q2 FY2024) and the six months then ended; comparisons are with the corresponding prior-year periods. Amounts below are in U.S. dollars unless noted.
Financial performance and liquidity
| Metric | Quarter | Six months |
|---|---|---|
| Net revenue | $318.2 million; up 7.0% reported and 7.6% constant currency | $629.5 million; up 12.6% reported and 13.6% constant currency |
| Gross profit / margin | $170.5 million / 53.6%, versus 53.1% | $337.8 million / 53.7%, unchanged |
| Operating income / margin | $35.3 million / 11.1%, down 24.5% | $89.0 million / 14.1%, up 14.8% |
| Net income | $24.9 million, down 25.0%; diluted EPS $0.48 versus $0.64 | $66.0 million, up 24.3%; diluted EPS $1.28 versus $1.03 |
| Operating cash flow | Not presented separately for the quarter | $118.2 million versus $129.0 million |
| Cash and liquidity | $351.0 million cash; working capital $601.5 million; current ratio 3.3 | |
| Debt | $762.2 million total carrying value, including $493.5 million net carrying value of 0% notes due 2026 and $269.5 million term loan. Net debt was $411.2 million. No revolving-facility borrowings; credit covenants were met. |
Quarterly revenue gains were led by Plasma (+11.0%) and Hospital (+13.5%); Blood Center declined 7.6%. Within Hospital, Vascular Closure grew 30.3% and Hemostasis Management 7.8%. For the six months, Plasma grew 21.8% and Hospital 13.0%, while Blood Center declined 2.8%.
Material changes versus prior comparable periods
Quarterly operating expenses rose 21.6% to $135.2 million, including a $10.4 million impairment of enicor-related intangibles, digital transformation costs and higher growth investment. Quarterly operating income and net income therefore fell despite higher revenue and gross margin. Over six months, operating income and net income increased, supported by revenue growth and operating leverage. Interest and other expense declined in both periods, mainly due to higher interest income and foreign-exchange effects, partly offset by higher term-loan interest.
Six-month operating cash flow decreased $10.8 million, primarily because of a $30.7 million cash use from inventory changes, partly offset by higher net income and lower accounts receivable. Investing cash use fell to $40.4 million from $89.3 million, principally reflecting lower capital expenditure; financing cash use fell to $7.8 million from $49.1 million, including the prior-year $75.0 million share repurchase.
Outlook, commentary, risks and unusual items
- Management said cash, operating cash flow and available credit are expected to fund requirements for at least the next twelve months. No specific revenue or earnings guidance was provided in the filing.
- The company agreed to acquire OpSens for CAD $2.90 per share, approximately $253 million in fully diluted equity value, with closing expected by the end of January 2024, subject to approvals and other conditions. It entered a CAD $345 million currency option to help manage transaction-related exchange risk.
- In November 2023, Haemonetics announced plans to discontinue ClotPro and whole-blood inline collection products and associated manufacturing. Management did not expect a material fiscal 2024 impact.
- An August 2023 voluntary recall of certain Whole Blood products resulted in cumulative charges of $6.5 million for inventory, returns and customer claims as of September 30; additional charges may follow. The filing separately identifies $4.3 million of inventory-related charges.
- The company recorded an approximately $8.7 million total accrual for an Illinois biometric-privacy class action after agreeing to terms in a memorandum of understanding intended to resolve the litigation. It also has a recorded loss contingency in a separate qui tam matter; no additional second-quarter adjustment was made.
- The Operational Excellence Program is expected to incur aggregate charges of $95–$105 million through fiscal 2025; cumulative charges were $71.4 million. Six-month restructuring and related costs were $4.2 million.
- Risks highlighted include product quality and recall exposure, customer concentration and demand, supply and raw-material costs, regulatory compliance, litigation, foreign exchange and interest rates, and successful execution of the OpSens acquisition and restructuring. The ERP rollout continues in phases through fiscal 2025; management reported effective disclosure controls as of quarter-end.
Important facts for investors to verify
- Whether the Whole Blood recall leads to further costs, regulatory action or customer effects.
- OpSens closing timing, financing and integration costs, and whether expected strategic benefits are achieved.
- Drivers of the divergence between revenue growth and lower quarterly operating income, including growth investment, impairment and ERP-related costs.
- Inventory levels and conversion to cash, given the inventory-related operating cash outflow.
- Resolution and final cost of the biometric-privacy and qui tam matters, and progress against the restructuring charge estimate.
- Debt service and covenant headroom, particularly the variable-rate term loan and June 2025 credit-facility maturity.